Loading...
BeiGene, Ltd.
BGNE•NASDAQ
HealthcareBiotechnology
$184.71
$0.90(0.49%)
BeiGene, Ltd. (BGNE) Financial Performance & Statements
Review BeiGene, Ltd.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
54.96%
↑ 54.96%
Operating Income Growth
52.95%
↑ 52.95%
Net Income Growth
26.87%
↑ 26.87%
Operating Cash Flow Growth
87.85%
↑ 87.85%
Operating Margin
-7.08%
↓ 7.08%
Gross Margin
84.81%
↑ 84.81%
Net Profit Margin
-9.40%
↓ 9.40%
ROE
-11.51%
↓ 11.51%
ROIC
-7.67%
↓ 7.67%
BeiGene, Ltd. (BGNE) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for BeiGene, Ltd. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $1.13B | $1.002B | $929.17M | $751.65M |
| Cost of Revenue | $160.56M | $170.46M | $138.13M | $124.94M |
| Gross Profit | $967.26M | $831.14M | $791.03M | $626.72M |
| Gross Profit Ratio | $0.86 | $0.83 | $0.85 | $0.83 |
| R&D Expenses | $542.01M | $496.18M | $454.47M | $460.64M |
| SG&A Expenses | $504.68M | $455.22M | $443.73M | $427.43M |
| Operating Expenses | $1.05B | $951.40M | $898.20M | $888.07M |
| Total Costs & Expenses | $1.21B | $1.12B | $1.04B | $1.01B |
| Interest Income | $7.81M | $10.64M | $13.22M | $16.16M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $50.25M | $71.29M | $24.11M | $25.29M |
| EBITDA | -$29.18M | -$48.97M | -$83.05M | -$236.06M |
| EBITDA Ratio | -$0.03 | -$0.05 | -$0.09 | -$0.31 |
| Operating Income | -$79.42M | -$120.27M | -$107.16M | -$261.35M |
| Operating Income Ratio | -$0.07 | -$0.12 | -$0.12 | -$0.35 |
| Other Income/Expenses (Net) | -$5.93M | $21.96M | $1.24M | $17.92M |
| Income Before Tax | -$85.35M | -$98.30M | -$105.92M | -$243.43M |
| Income Before Tax Ratio | -$0.08 | -$0.10 | -$0.11 | -$0.32 |
| Income Tax Expense | $66.53M | $23.05M | $14.48M | $7.72M |
| Net Income | -$151.88M | -$121.35M | -$120.41M | -$251.15M |
| Net Income Ratio | -$0.13 | -$0.12 | -$0.13 | -$0.33 |
| EPS | -$0.11 | -$0.09 | -$0.09 | -$0.19 |
| Diluted EPS | -$0.11 | -$0.09 | -$0.09 | -$0.19 |
| Weighted Avg Shares Outstanding | $1.36B | $1.36B | $1.36B | $1.36B |
| Weighted Avg Shares Outstanding (Diluted) | $1.36B | $1.36B | $1.36B | $1.36B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan